Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Exclusion Criteria

• •12. No obvious hereditary diseases.
• •13. Able to understand the requirements and matters of the trial, and willing to participate in clinical research as required.
• •14. Informed consent must be signed.
• •1. During the screening period, there was central nervous system (CNS) invasion or a history of clinically significant central nervous system diseases, such as epilepsy and cerebrovascular diseases.
• •2. Women who are pregnant or breastfeeding, or who do not agree to use effective contraception during treatment and during the subsequent 1 year.
• •3. History of allogeneic hematopoietic stem cell transplantation, or organ transplantation.
• •4. History of other malignancies that have not been in remission.
• •5. Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy.
• •6. Received radiotherapy within 3 months before enrollment.
• •7. Received immunotherapy drugs within 4 weeks before enrollment, such as anti-programmed death 1 (PD-1) antibody, anti-programmed death ligand 1 (PD-L1) antibody, CD19/CD3-bispecific antibody, and so on.
• •8. Patients who received any immunocellular therapy within 6 months before enrollment.
• •9. Confirmed evidence showing positiveness of anti-CD19 scFv reaction in patient serum.
• •10. Patients who participated in other clinical trials within 4 weeks prior to enrollment.
• •11. Uncontrolled infectious diseases or other serious illnesses, including but not limited to infections \[e.g., human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B (HBV) or C (HCV) infection\], congestive heart failure, unstable angina, arrhythmias, or that pose an unpredictable risk in the opinion of the attending physician.
• •12. The presence of uncontrollable serous membrane fluid, such as massive pleural effusion or ascites.
• •13. A history of stroke or intracranial hemorrhage within 3 months prior to enrollment.
• •14. Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered.
• •15. Received allogeneic cell therapy within 6 weeks prior to enrollment, such as donor lymphocyte infusion.
• •16. History of allergies to any of the ingredients in cell products.
• •17. Conditions in which a known mental or physical illness interferes with cooperation with the requirements of the study or disrupts the results or interpretation of the results and, in the opinion of the therapeutic investigator, makes the patient unfit for study participation.
• •18. There is the situation that the researcher's judgment will interfere with the whole study participation; Situations where there is significant risk to the subject; Or interferes with the interpretation of research data.
• •19. Inability to understand or unwillingness to sign informed consent.
• •20. Researchers believe that other reasons are not suitable for clinical trials.